Syngenta, a global agricultural giant, has ceased sales of its paraquat herbicide in Australia and New Zealand, citing the product's commercial unviability. The company's decision follows new restrictions imposed by the Australian Pesticides and Veterinary Medicines Authority (APVMA) last month, which, alongside a "highly complex and increasingly expensive supply chain," rendered the product unprofitable for the corporation.
Managing director David Van Ryswyk stated on Friday that "Regulatory constraints, combined with a highly complex and increasingly expensive supply chain, have made the paraquat herbicide products commercially unviable." This move comes after Syngenta announced plans in March to end paraquat production at its UK plant, ceasing global output by the end of June. The company had initially confirmed a commitment to supplying Australian farmers via a third-party manufacturer, an arrangement now also terminated.
Profit Over Public Health
Syngenta's exit from the market is a clear act of capital flight, abandoning a product when its profit margins are squeezed by even minimal regulatory oversight. Mr. Van Ryswyk explicitly linked the decision to profitability, declaring, "Dedicating significant resources to unprofitable legacy products is no longer sustainable." He added that this "difficult" decision allows the company to "redirect our resources," a common corporate euphemism for shifting capital to more lucrative ventures. For decades, Syngenta had been the "stable foundation" of the paraquat market in Australia, according to Western Victorian farmer Andrew Weidemann.
The State's Limited Hand
The APVMA, Australia's national regulator, introduced new limits and conditions on paraquat use last month. However, the authority stopped short of an outright ban, despite public health concerns. The regulator concluded there was "no evidence the chemical increased the risk of Parkinson's disease if used safely with the authority's significant restrictions in place." This regulatory stance highlights the state's role in managing, rather than challenging, the operations of capital, allowing potentially harmful chemicals to remain in circulation under conditions that shift the burden of safety onto users. The APVMA, in its own statement, confirmed it "does not comment on the commercial decisions of individual companies," underscoring its neutrality in the face of corporate profit motives.
Costs Shifted Downward
While Syngenta exits, generic versions of paraquat will still be sold in Australia by other companies, many "coming out of China," according to Mr. Weidemann. This ensures the chemical remains available, but the costs of compliance and adaptation are now offloaded onto the agricultural sector. Mr. Weidemann, a spokesman for Grain Producers Australia, voiced concern that Syngenta's withdrawal "leaves some important questions about what happens next." He specifically noted that the work to implement new label changes, such as "changes in grams active and the withholding periods on late applications in crop," will "fall clearly on the feet of the industry." This represents a direct cost transfer from a multinational corporation to farmers, who will "have to work through" these new expenses. Syngenta stated it would manage the phase-out of its products in "strict alignment" with APVMA timelines, ensuring a smooth transition for its own financial interests.